Compare GSK plc (GSK) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Weibo Corp — how do they compare? GSK plc trades at $46.55 (market cap $91.88B), while Weibo Corp trades at $6.55 (market cap $1.56B). The key difference: GSK plc is far larger — about 58.9× Weibo Corp's market cap, and Weibo Corp pays the higher dividend (9.47%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Weibo Corp for 102 Days on average.
| GSK | WB | |
|---|---|---|
Market Cap | $91.88B | $1.56B |
Volume | 7,730,529 | 812,503 |
Sector | Health | Media |
52-Week High | $61.18 | $12.37 |
52-Week Low | $43.24 | $6.33 |
Typical Hold Time | 93 Days | 102 Days |
Enterprise Value | $111.88B | $786.69M |
Dividend Yield | 3.9% | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Weibo (WB) trades at $6.55, up 1.08% with bearish technical indicators but attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported Q2 2026 earnings beat with $449M net income in 2025, though recent quarters show mixed results. Cash flow trends show volatility with a $694M net outflow in 2024, while analyst sentiment remains divided with 40.9% buy ratings amid concerns about user growth stagnation.
WB presents as a deep-value opportunity with strong profitability margins but faces significant headwinds from declining user metrics and advertising challenges. The stock's low valuation multiples suggest potential upside if operational stability improves, though competitive pressures and China's regulatory environment remain key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
